PSY37 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 600/800mg Daily as Therapy for Imatinib Failing Chronic Myeloid Leukemia (CML)
Abstract
Authors
M. Taylor S. Mealing D. Scott J. Clark M. McKenna M. Lebmeier C. Davis